Back to top
more

Gilead Sciences (GILD)

(Real Time Quote from BATS)

$74.47 USD

74.47
1,733,033

+0.69 (0.94%)

Updated Aug 19, 2024 03:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (70 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Gilead Files sNDA for Label Expansion of HIV Therapy Descovy

by Zacks Equity Research

Gilead (GILD) submits sNDA to the FDA for label expansion of Descovy as PrEP to reduce the risk of sexually acquired HIV-1 infection.

Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Gilead Sciences (GILD) closed the most recent trading day at $65.88, moving +1.34% from the previous trading session.

Ekta Bagri headshot

NASH Scorecard So Far This Year: A Look at the Hits & Misses

by Ekta Bagri

NASH is a highly lucrative market with blockbuster potential. Let us take a look at the winners and losers in this space so far in 2019.

Gilead & Galapagos Announce Positive Data on Arthritis Drug

by Zacks Equity Research

Gilead (GILD) and partner Galapagos announce positive results from late-stage studies on investigational drug, filgotinib for the treatment of RA.

Biotech Stock Roundup: BIIB & CNAT Crash on Study Failures, LXRX Gets CRL

by Zacks Equity Research

Key highlights of the past week are multiple study failures and other pipeline updates.

Gilead Sciences (GILD) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Gilead Sciences (GILD) closed the most recent trading day at $63.88, moving +0.17% from the previous trading session.

Conatus (CNAT) Declines on Failure of NASH Fibrosis Study

by Zacks Equity Research

Conatus' (CNAT) stock plunges as the phase IIb study on emricasan for the treatment of biopsy-confirmed NASH and liver fibrosis fails.

Gilead Sciences (GILD) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Gilead Sciences (GILD) closed at $65.49, marking a +0.72% move from the previous day.

YETI, Gilead, Dick's, FedEx and Amazon highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

YETI, Gilead, Dick's, FedEx and Amazon highlighted as Zacks Bull and Bear of the Day

Madeleine Johnson headshot

Bear of the Day: Gilead Sciences (GILD)

by Madeleine Johnson

The potential for revenue growth looks shaky for this biotech giant.

Agenus Wins $7.5M Milestone Payment From Gilead, Stock Up

by Zacks Equity Research

Agenus (AGEN) gets a $7.5-million milestone payment from Gilead following the FDA acceptance of the company's IND filing for AGEN1423. Shares rise.

Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Gilead Sciences (GILD) closed the most recent trading day at $65.75, moving +1.42% from the previous trading session.

Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy

by Zacks Equity Research

Gilead (GILD) presents encouraging data on two leading HIV regimens, Bikatrvy and Descovy.

Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy

by Zacks Equity Research

Gilead (GILD) presents encouraging data on two leading HIV regimens, Bikatrvy and Descovy.

Why Is Gilead (GILD) Down 4.9% Since Last Earnings Report?

by Zacks Equity Research

Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Intercept (ICPT) Up on Q4 Revenue Beat, NASH Study in Focus

by Zacks Equity Research

Intercept's (ICPT) Q4 revenues top estimates owing to strong Ocaliva sales, driven by sales force expansion and growth in its foreign geographies.

Nektar (NKTR) Q4 Earnings Beat, NKTR-181 Review Extended

by Zacks Equity Research

Nektar's (NKTR) earnings and sales beat estimates in the fourth quarter. The FDA extends the review period for NKTR-181 NDA by three months.

The Zacks Analyst Blog Highlights: Intercept, Gilead, Vertex, Alkermes and Clovis

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Intercept, Gilead, Vertex, Alkermes and Clovis

Biotech Stock Roundup: ICPT Strong on NASH Drug Data, Collaborations & More

by Zacks Equity Research

Key highlights of the past week are regulatory and pipeline developments along with research collaboration deals.

Intercept Reports Positive Top-Line Data for NASH, Shares Up

by Zacks Equity Research

Intercept (ICPT) reports positive top-line results from its pivotal phase III REGENERATE study of OCA in patients with liver fibrosis due to NASH.

Sanghamitra Saha headshot

Despite M&A Spree, Biotech ETFs Slide on Mixed Earnings

by Sanghamitra Saha

Biotech stocks came up with mixed earnings and weighed on the related ETFs in the key reporting season.

Biotech Stock Roundup: Regeneron Impresses in Q4, Gilead Slumps, MacroGenics Soars

by Zacks Equity Research

Key highlights of the week were fourth-quarter results from Regeneron Pharmaceuticals and Ligand Pharmaceuticals along with other regulatory and pipeline updates.

Gilead's (GILD) Late-Stage Study on Liver Disease Drug Fails

by Zacks Equity Research

Gilead (GILD) suffers a setback as its phase III study on pipeline candidate, selonsertib, in patients with compensated cirrhosis (F4) due to NASH fails to meet goal.

The Zacks Analyst Blog Highlights: Gilead, Vertex, Celgene, Alkermes and AVEO

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Gilead, Vertex, Celgene, Alkermes and AVEO

Biotech Stock Roundup: Celgene Tops in Q4, Gilead Disappoints, ALKS & AVEO Sink

by Zacks Equity Research

Key highlights of the week were the fourth-quarter results by biotech bigwigs Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX) and Celgene (CELG).